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Abstract
Background: Use of drug delivery devices between nebulizers, dry powder inhalers (DPIs), or metered dose inhalers
(MDIs), for treating patients with asthma and chronic obstructive pulmonary disease (COPD), is based on patients’
capability of coordinating the inhalation maneuver and achieving sufficient airflow. There are limited data available
with regard to how patients meet the requirements of successful inhalation performance, and how the concept of
inspiratory lungpower could be applied. The aim of this work was to study the patient inspiratory airflow profile
performance in large data sets. We analyzed how the Kamin-Haidl inhalation criteria were met by patients with DPIs
such as Easyhaler for combination therapy (EH-combi), Easyhaler for monotherapy (EH-mono), Diskus, and Tur-
buhaler (TH), and applied peak lungpower instead of peak inspiratory flow rate as an indicator of patient performance.
Materials and Methods: Data sets gathered in two previous studies for DPIs, that is, EH-combi, EH-mono,
Diskus, and TH, were used to analyze how inspiratory lungpower representing inspiratory muscle power, flow
acceleration, and volume after peak met the inhalation criteria. The measured patient airflow profiles through
inhalers were assessed for patients with asthma or COPD.
Results: Based on the Kamin-Haidl inhalation criteria, successful inhalation requirements were met with EH-
combi in 96.1% and with EH-mono in 92.6% of patients. The success rates were 89.5% and 84.6% with Diskus
and TH, respectively, ( p < 0.0001 between devices). In patients with asthma or COPD, the mean lungpower was
7.51 and 6.15 W for EH-combi, 8.79 and 6.88 W for EH-mono, 7.18 and 4.36 W for Diskus, and 9.65 and 6.86
W for TH, respectively, when patients followed the manufacturer’s written instructions.
Conclusions: Lungpower applied to the Kamin-Haidl inhalation criteria concept could be an applicable method
for reviewing patient performance for different DPIs despite DPIs’ characteristic differences in airflow resistance.
In light of these results, DPIs provide a feasible treatment option for a large majority of respiratory patients.
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Introduction
Adegree of misinterpretation relates to the patientinspiratory flow rate with respect to inhalation capabil-
ity. The discussion on inspiratory effort has been based
mostly on achieved peak inspiratory flow (PIF) alone, which
may lead to erroneous conclusions unless the inhaler’s air-
flow resistance is also considered. The PIF does not translate
well between inhalers with different airflow resistances, as
lower the resistance, the higher the flow rate will be. The
concept of lungpower, defined in equation [3], takes into
account both airflow resistance and airflow and could provide
better means for representing the patient inspiratory muscle
power.(1–6)
In the 1960s, the respiratory muscle strength determina-
tion method was developed by Black and Hyatt and defined
as maximum inspiratory pressure (MIP) when measured at
fixed airflow resistance.(4) The MIP measurement was carried
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out inhaling and exhaling through a cylindrical tube with a
small opening of B2 mm · 15 mm, reducing the excessive
mouth pressure compared with closed volume(4,5) and mea-
suring the generated mouth pressure. The small hole in this
setup is analogous to airflow resistance of an inhaler. MIP de-
scribing inspiratory muscle strength was defined as pressure
with the given fixed airflow resistance; later, for example,
100 cm/H2O at 220 mL/s flow ( = 0.24 OkPa min/L) by En-
right.(5) This MIP measurement procedure has been in use for a
long time, with minor modifications. For example, de Köning
used a modified setup using a resistance of 0.039 OkPa min/L.(7)
By equation [1], PIF has a negative correlation to inhaler re-
sistance, whereas pressure drop has a positive correlation.
Kamin et al. defined criteria for assessing successful in-
halation maneuver.(8,9) The work was continued by Haidl
et al. by extensive literature review looking at different in-
halation devices, in vitro evidence, and most-suited inhala-
tion maneuver.(10) The Kamin-Haidl criterion for PIF is
30 L/min for Easyhaler for combination therapy (EH-combi),
Easyhaler for monotherapy (EH-mono), and Diskus.(9–16)
PIF recommendation for Turbuhaler (TH) is higher
(60 L/min)(8,9,17,18) than for many other dry powder inhalers
(DPIs) based on the findings of TH’s high airflow depen-
dency in low-to-medium airflows.(10,19) The acceleration
criterion(8–10) for all these devices is 0.7 L/s2 and the re-
quirement for inhalation volume is 500 mL after reaching the
peak flow rate. These Kamin-Haidl criteria are represented in
Table 1. Haidl’s work was further continued by Pohlmann
et al. using the concept of lungpower and examined the
minimum peak lungpower criterion with a small group of
subjects for inhalers based on Haidl’s values.(8–10,19)
Dunbar et al.(20) investigated power using 1, 2, and 3 W
power in his in vitro performance work. They showed on
two different devices out of three that DPIs can deliver
drugs already at a power of 1 W. Dunbar et al. concluded
that lungpower could be an applicable method studying
inhalers with different resistances in a comparable manner,
but it would be important to investigate applicable power
levels on clinical setting.
We used Kamin-Haidl inhalation criteria for inhalation
performance assessment. We replaced PIF by using conver-
sion to lungpower according to equation [3] and included
inhalation acceleration and volume after the peak determi-
nation. We also investigated how peak lungpower relates to
the achieved airflows and pressure drops using different in-
halers. We analyzed patient peak lungpower data based on
PIF-studies that were carried out for four different DPIs.(21,22)
Materials and Methods
The PIF rate studies for this work have been previously
reported in detail by Malmberg et al.(21) and Jõgi et al.(22)
Briefly, the study population included children, adults, and
elderly patients with asthma or chronic obstructive pulmo-
nary disease (COPD).
There were 187 patients included in the study by
Malmberg et al. and 227 patients in the study by Jõgi et al.
From the studies, 17 patients were excluded from per pro-
tocol analyses. In addition, 14 subjects younger than 6 years
from the study by Jõgi et al. were excluded further from the
analyses. Thus, the total number of subjects in this study is
383. Out of these, 287 were asthmatics and 96 were patients
with COPD. The inhalation profile data were available for
363, 202, 200, and 162 patients for EH-combi, EH-mono,
Diskus, and TH, respectively.
In these studies, the lactose placebo-filled commercial
DPI products of budesonide/formoterol Easyhaler (EH-
combi) (Orion Pharma, Finland), budesonide Easyhaler (EH-
mono) (Orion Pharma), salmeterol/fluticasone Easyhaler
(EH-combi) (Orion Pharma), salmeterol/fluticasone Diskus
(Diskus) (GSK Pharma, United Kingdom), and budesonide/
formoterol TH (AstraZeneca, United Kingdom) were used.
Inhaler airflow resistances were 0.036 OkPa min/L for
EH-combi, 0.044 for EH-mono, 0.027 for Diskus, and 0.032
for TH (TH M3-version).(21,22)
The inhalation flow profile measurements were conducted
according to manufacturer’s written instructions (patient in-
formation leaflets) to conduct the inhalation maneuver as they
are taught in real-life use. The PIFs and volumes through
inhalers were identified for patients with asthma or COPD.
Inhalation maneuver instructions for the study by Malm-
berg et al. and the study by Jõgi et al. are provided in Table 2.
Inhalation flow profile
Complete inspiratory flow profiles through inhalers were
recorded using pneumotachograph (Spiromaster MX; Med-
ikro Ltd., Kuopio, Finland), including pressure drops, and
inspiratory volumes. For the purposes of this study, the
complete inspiratory flow data sets that were measured at
100 Hz (10 ms) interval were reanalyzed. Further analysis on
the flow profile data was conducted for PIF rate time point
and inhaled volume beyond the PIF.
Kamin-Haidl inhalation criteria and lungpower
The Kamin-Haidl(9,10) inhalation criteria were used for
inhalation performance assessment. PIF was converted to
Table 1. Kamin-Haidl Inhalation Criteria
Kamin-Haidl inhalation criteria
PIF ‡30 L/mina
Inhalation acceleration ‡0.7 L/s2
Inhalation volume ‡500 mL after PIF
aTH 60 L/min10
PIF, peak inspiratory flow; TH, Turbuhaler.
Table 2. The Applied Inhalation Maneuver




EH-combi Take a strong and deep breath through
the Easyhaler.
EH-mono Take a strong and deep breath through
the Easyhaler.
Diskus Breathe in steadily and deeply through
the Diskus, not through your nose.
TH Breathe in as deeply and as hard as you
can through your mouth.
EH-combi, Easyhaler for combination therapy; EH-mono, Easy-
haler for monotherapy.
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lungpower by applying equation [3].(19) Inhalation acceler-
ation and volume after the peak determination were used as
presented by the original authors. All three criteria were to
be met during the same inhalation maneuver for a successful
attempt.
Clark & Hollingworth(23) provide equation [1] for the
pressure drop within the inhaler system for turbulent flow.
p
DP¼Q · R DP for pressure drop,ð
Q for airflow and R for airflow resistanceÞ
[1]
Harris applied the concept of air watts(2,3) with respect to
equation [2] for inhaler’s vacuum power.
P¼Q ·DP P for Power, Q for airflow andð
DP for pressure dropÞ
[2]
Equation [3] was introduced by Dunbar et al., which can
be originated from [1] and [2], and it gives lungpower as a
function of airflow and resistance.(20,24)
P¼Q3  R2 P for Power, Q for airflow andð
R for airflow resistanceÞ
[3]
With the commonly used units in inhalation literature for
Q (L/min) and R (OkPa min/L) unit conversion into SI-base
units of m/s and OkPa s/L this is written as follows:
P¼ Q=60ð Þ3  60  Rð Þ2 [4]
When converting the PIF from Kamin-Haidl criteria to
lungpower according to equation [3] at a recommended flow
of 30 L/min, the peak lungpower acceptance criteria were
0.58 W for EH-combi, 0.87 W for EH-mono, and 0.33 W for
Diskus. The TH lungpower threshold value is 3.69 W
based on 0.032 OkPa min/L resistance at a recommended
60 L/min PIF.
Peak time, airflow acceleration, and volume after peak
Peak time is the time point in the inspiratory flow profile
where the maximum inspiratory flow rate occurs. Flow accel-
eration [or flow increase rate (FIR)] was calculated as the nu-
merical derivative of the flow rate, as described in equation [5].
FIR¼DQ=Dt [5]
For the acceleration, we used 10 L/min as lower end and
80% of the maximum as upper limit for the derivation. In
literature, 20% of the maximum is often used as a lower
limit.(2,7) However, we consider our approach valid since it
correctly identified the linear region of the patient inhalation
profile curve. Acceptance criteria according to Kamin-Haidl
were for acceleration 0.7 m/s2 and for volume 500 mL after
the peak.(9,10)
Inhalation work
Inhalation work was calculated by determining lung-
power area under the curve for the duration of the inhalation
maneuver according to equation [6]. The airflow is mea-
sured with the mentioned Spiromaster MX pneumotacho-
graph, and lungpower calculated according to equation [4]






Pairwise comparisons of inhalers according to the Kamin-
Haidl criteria were performed using McNemar’s test. All
descriptive statistics and statistical comparisons were per-
formed with SAS ver. 9.4 (SAS Institute, Inc., Cary, NC).
Results
Inhalation flow profile
The Malmberg et al. and Jõgi et al. inhalation profile char-
acteristics were compiled from the studies and are presented in
Table 3.
For performance assessment, we analyzed the inhalation
profiles for lungpower, the timing when the peak flow rate
was achieved (Tmax), acceleration rate, and inhalation
work. The results are provided in Table 4.
Kamin-Haidl inhalation criteria and lungpower
For assessing the successful inhalation rates for different
devices, we used complete flow profile data, where in ad-
dition to lungpower and acceleration rate, we checked that
Table 3. Mean Peak Inspiratory Flow (L/Min) and Inspiratory Volume Through EH-Combi, EH-Mono,
Diskus, and Turbuhaler Inhalers in Patients with Asthma or Chronic Obstructive Pulmonary Disease
(Per-Protocol Data Set)
(21,22)
Patients with asthma Patients with COPD
n PIF (std) Volume (std) n PIF (std) Volume (std)
EH-combi 287 66.7 (13.4) 1.9 (0.7) 96 61.9 (13.2) 1.8 (0.7)
EH-mono 150 60.9 (12.0) 2.0 (0.7) 52 58.2 (8.6) 1.9 (0.6)
Diskus 150 76.6 (20.0) 2.3 (0.9) 52 65.1 (19.0) 2.2 (0.7)
TH 137 79.4 (14.4) 1.9 (0.7) 44 72.1 (15.1) 1.8 (0.6)
N reflects the obtained PIF and volume values in the studies and thus differs slightly from the obtained number of inhalation profiles.
COPD, chronic obstructive pulmonary disease.
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500 mL inhalation volume after the PIF was reached. The
analyses of the different parameters for Kamin-Haidl inha-
lation criteria are summarized in Table 5 and Figure 1A–D.
For calculation of the lungpower, the pressure drops were
measured first as described and values used for calculating
PIF according to equation [1]. The pressure drop results are
compiled in Table 6. For the EH-combi, the mean peak
pressure drop for patients with asthma was 6.15 kPa (95%
confidence interval [CI]: 5.86–6.45), EH-mono 7.75 kPa
(7.17–8.33), Diskus 4.78 (4.34–5.22), and TH 6.80 kPa
(6.40–7.21), respectively. For patients with COPD, the mean
peak value for EH-combi was 5.41 kPa (4.96–5.85), for EH-
mono 6.76 kPa (6.22–7.30), for Diskus 3.43 kPa (2.89–3.98),
and for TH 5.37 (4.65–6.09), respectively. The 10th and
90th percentile peak pressure values followed the same in-
haler rank order for the two different patient groups similar
to the means. The range for 10th percentile was from 1.89 to
4.11 kPa for patients with asthma and from 1.63 to 4.65 kPa
for patients with COPD. In turn, 90th percentile values were
from 9.28 to 10.87 kPa for patients with asthma and from
5.74 to 9.54 kPa for patients with COPD.
The peak lungpower mean values with the four devices
were between 7.18 and 9.65 W for patients with asthma, and
from 4.36 to 6.88 W for patients with COPD. For EH-
combi, the mean peak value was 7.51 W (95% CI: 6.95–
8.07) for asthmatics and 6.15 W (5.42–6.88) for patients
with COPD. For EH-mono, the measured peak lungpower
mean was 8.79 W (7.63–10.0) for patients with asthma and
6.88 W (6.06–7.69) for patients with COPD. The lowest
values were obtained with Diskus for patients with asthma,
7.18 W (6.02–8.33), and patients with COPD produced 4.36
W (3.302–5.43) of peak lungpower, whereas TH results
were 9.65 W (8.79–10.52) for asthmatics and 6.86 W (5.56–
8.16) for patients with COPD. The peak lungpower results
are illustrated in Figure 1B.
Kamin-Haidl inhalation criteria were met for 96.1% (95%
CI: 94.2–98.1) of EH-combi, 92.6% (88.9–96.2) of EH-
mono, 89.5% (85.2–93.8) of Diskus users, and 84.6% (78.9–
90.2) of TH. The performances on different inhalers are
shown in Figure 1A.
Peak time, airflow acceleration,
and volume after the peak
The mean peak timings (Tmax) were for patients with
asthma with EH-combi 0.57 second (95% CI: 0.53–0.60),
EH-mono 0.60 second (0.55–0.65), Diskus 0.88 second
(0.78–0.98), and TH 0.48 second (0.45–0.52), respectively.
Correspondingly, for patients with COPD EH-combi, these
were 0.47 second (0.44–0.50), EH-mono 0.54 second (0.48–
0.60), Diskus 0.90 second (0.73–1.07), and TH 0.48 second
(0.41–0.55), respectively.
The mean acceleration for EH-combi was 4.27 L/s2 (95%
CI: 3.96–4.59) and 4.16 L/s2 (3.71–4.61) for asthmatics and
COPD patients, respectively. EH-mono had very similar
mean results between asthmatics and COPD patients,
3.84 L/s2 (3.45–4.24) versus 3.66 L/s2 (3.16–4.16), while the
10th percentile differed slightly, being 0.98 versus1.65 L/s2.
Acceleration on TH measured similar values 5.42 L/s2 (4.96–
5.88) and 5.17 L/s2 (4.18–6.17) for both patient groups. Re-
sults for COPD patients with Diskus were lowest 2.85 L/s2
(2.20–3.50), and 0.77 L/s2 by 10th percentile. Patients with
asthma reached mean value of 3.78 L/s2 (3.24–4.32) with
Diskus. The patient accelerations are shown in Figure 1D.
For patients with asthma, mean volume after the peak was
for EH-combi 1.47 L (95% CI: 1.39–1.55), EH-mono 1.55 L
(1.43–1.67), Diskus 1.47 L (1.35–1.60), and for TH 1.47 L
(1.36–1.59). In turn, for patients with COPD, the results
were 1.44 L (1.32–1.56), EH-mono 1.50 L (1.35–1.64),
Diskus 1.47 L (1.31–1.63), and for TH 1.26 L (1.11–1.41),





























Asthma EH-combi (0.036) 7.51 (4.73) 2.77 13.08 0.57 (0.30) 4.27 (2.67) 1.45 7.06 8.43 (7.97)
EH-mono (0.044) 8.79 (7.24) 3.18 13.61 0.60 (0.30) 3.84 (2.47) 0.98 6.86 11.43 (14.78)
DISKUS (0.027) 7.18 (7.14) 1.61 13.35 0.88 (0.62) 3.78 (3.32) 0.86 7.50 7.77 (9.34)
TH (0.032) 9.65 (4.92) 3.69 15.67 0.48 (0.20) 5.42 (2.62) 2.42 9.33 8.93 (6.12)
COPD EH-combi (0.036) 6.15 (3.42) 2.21 11.74 0.47 (0.14) 4.16 (2.10) 1.93 6.51 6.55 (4.34)
EH-mono (0.044) 6.88 (2.93) 3.84 11.16 0.54 (0.22) 3.66 (1.80) 1.65 6.39 8.23 (4.12)
DISKUS (0.027) 4.36 (3.78) 1.29 8.51 0.90 (0.60) 2.85 (2.31) 0.77 5.49 4.85 (3.26)
TH (0.032) 6.86 (3.78) 1.96 11.47 0.48 (0.20) 5.17 (2.91) 2.19 7.30 6.27 (4.20)
Table 5. Successful Inhalation Performance Attempts and Percentage












EH-combi (n 363) 360 (99.2%) 357 (98.4%) 353 (97.3%) 349 (96.1%)
EH-mono (n 202) 199 (98.5%) 194 (96.0%) 192 (95.1%) 187 (92.6%)
Diskus (n 200) 198 (99.0%) 185 (92.5%) 190 (95.0%) 179 (89.5%)
TH (n 162) 139 (85.8%) 162 (100%) 158 (97.5%) 137 (84.6%)
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respectively. Figure 1C illustrates patient volume after the
peak performance.
Inhalation work
The inhalation work was relatively similar among pa-
tients with asthma having mean inhalation work for EH-
combi 8.43 J (95% CI: 7.49–9.37), Diskus 7.77 J (6.26–
9.29), and TH 8.93 J (7.86–10.01). EH-mono measured
higher, 11.43 J (9.04–13.81). For the COPD patients, EH-
combi and TH were similar with measured work of 6.55 J
(5.62–7.49) and 6.27 J (4.83–7.72), respectively. EH-mono
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FIG. 1. Patient inhalation performance for EH-combi, EH-mono, Diskus, and TH. (A) Successful inhalation rate (Kamin-
Haidl) for EH-combi, EH-mono, Diskus, and TH. (B) Peak lungpower for EH-combi, EH-mono, Diskus, and TH.
(C) Inhalation volume after peak for EH-combi, EH-mono, Diskus, and TH (the horizontal line in figures B–D represents
success criterion). (D) Inhalation acceleration for EH-combi, EH-mono, Diskus, and TH. EH-combi, Easyhaler for com-
bination therapy; EH-mono, Easyhaler for monotherapy; TH, Turbuhaler.
Table 6. Measured Pressure Drop Characteristics for Patients with Asthma













Asthma EH-combi (277) 6.15 5.86 6.45 3.31 9.28
EH-mono (150) 7.75 7.17 8.33 4.11 10.87
Diskus (149) 4.78 4.34 5.22 1.89 7.77
TH (127) 6.80 6.40 7.21 3.65 9.65
COPD EH-combi (86) 5.41 4.96 5.85 2.83 8.68
EH-mono (52) 6.76 6.22 7.30 4.65 9.54
Diskus (51) 3.43 2.89 3.98 1.63 5.74
TH (35) 5.37 4.65 6.09 2.44 7.84
CL, confidence limit.
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Relevance of lungpower in airflow dependency testing
We observed that patients seldom (in total, 11 out of 383
patients) exceeded the peak lungpower of 20 W. Conse-
quently, the flow rates had device-specific area of relevance
for peak lungpowers of 0–20 W. Table 7 provides calcula-
tions for EH-combi, EH-mono, TH, and Diskus with the
flow rate-specific lungpower values. These power values
provide patient inspiratory effort comparability from one
device to another with a given airflow.
Table 7 shows that the flow rates would be limited by
patients’ lungpower with higher resistance devices only at
very high flow rates. Airflow of 90 L/min flow already
represents 23.5 W of lungpower with high resistance EH-
mono. This is nearly three times the lungpower than that
with medium resistance Diskus (8.86 W) with the same
airflow. We observed that applying fixed airflows of, for
example, common 30, 60, and 90 L/min do not indicate the
same patient population groups at 60 and 90 L/min regard-
ing inspiratory muscle strength with devices of different
airflow resistances.
Discussion
The inhaler prescription routine follows the principles of first
selecting the appropriate active substance and dose for the pa-
tient. The device selection (nebulizer, metered dose inhaler
[MDI], DPI) for the patient can be based on the patient’s capa-
bility to coordinate the maneuver and inhalation efficiency.(17)
Very young children or patients, who cannot coordinate their
actuation/inhalation maneuver or do not achieve the re-
commended PIF threshold via a DPI (most often 30 L/min)
could be recommended to use a nebulizer or MDI. DPIs are an
alternative for patients who achieve the threshold flow as they
resolve the coordination requirements related with MDIs.(17)
Inhalers can provide different deagglomeration efficacy at
same airflow if device’s resistance and design are different.(17)
In some inhalers such as EH, the particles are locally accel-
erated utilizing the Bernoulli principle. The Bernoulli law
holds also for gasses as long as the velocity is sufficiently low
(<1/3 speed of sound) for them to be treated as incompressible.
The particle wall collisions are intended to occur when the
kinetic energy of the particles is at the maximum leading to
high fine particle fraction (FPF). When deagglomeration has
taken place, the particles are slowed down again in an ex-
panded flow tube and further in the mouth. In EH, the airflow
resistance results from the flow constriction and is therefore an
important feature of the device. It does not increase or decrease
the total energy that is fed into the system by the patient and
that is provided for particle dispersion.
For TH, we noted that the higher minimum peak lung-
power requirement due to higher minimum flow require-
ment(8,9,17,18) has led to special emphasis on instruction
language: ‘‘breathe in as deeply and as hard as you can
through your mouth.’’ This instruction update was studied
and results were reported by Persson et al.(25) TH instruction
language encourages the patients to take their best effort in
inhalation maneuver and that can be seen from slightly
higher lungpower recordings than for other devices. Ac-
cording to Persson et al., this increased PIF in average 20%
compared with the old instruction ‘‘take a deep inhalation
from the inhaler.’’(25) In turn, the inhalation instruction
language for Diskus is similar to many MDIs and states that
patient should ‘‘breathe in steadily and deeply.’’ It was
discussed by Broeders et al.(26) that the wording may com-
promise the effort by the patient, which converts to lower
than expected inhalation acceleration. Whether the same
inhalation instructions for all devices would measure the
same lungpower regardless of resistance is an area of further
studies.
For patients with asthma, the measured lungpower mean
was from 6 W to 10 W, and from 4 to 7 W for patients with
COPD. The lowest values were recorded for Diskus, 4 W,
by patients with COPD. For DPI usage, these observed
lungpowers are plentiful in comparison with minimum
criteria of Pohlmann.(19) For EH-combi, the threshold
according to formula [3] would be 0.6 W, and Pohlmann
had determined the threshold for EH-mono as 1.2 W, TH
4.4 W, and Diskus 0.3 W.(16) Therefore, we believe that
patient peak lungpower does not limit the use of DPIs as
the minimum peak lungpower criteria were met to high
degree by both EH and Diskus users and only with TH
patients, capability was slightly compromised. For veri-
fying our results, we back-calculated Enright et al.’s(5)
1994 work; Respiratory Muscle Strength in the Elderly
(4443 participants, 65 years and older, men and female),
MIP. We found that indeed the mean peak lungpower
levels are 7.15–16.10 W for men and 3.65–7.94 W for
women. This Enright study uses a setup that has a resis-
tance of 0.24 OkPa min/L, nearly 10-fold of medium re-
sistance inhaler and still the results in power make sense
in comparison with our findings.
Based on the measured Tmax,(25) acceleration, and com-
parison to literature, for example, Azouz et al.(27) (who en-
couraged patients to inhale as they normally would) provide
further evidence that the device’s instruction language may
have significance on patient’s performance.(25,26) This may
explain the contradictionary results of observing the longest
Tmax and lowest acceleration with Diskus that has lowest
resistance opposite to learnings in the literature.(6,27)




30 40 50 60 70 80 90 100 110 120
EH-mono 0.044 0.87 2.07 4.03 6.97 11.07 16.52 23.52 32.27 42.95 55.76
EH-combi 0.036 0.58 1.38 2.70 4.67 7.41 11.06 15.75 21.60 28.75 37.32
TH 0.032 0.46 1.09 2.13 3.69 5.85 8.74 12.44 17.07 22.72 29.49
Diskus 0.027 0.33 0.78 1.52 2.62 4.17 6.22 8.86 12.15 16.17 21.00
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The volume after the peak was very similar between all
tested devices and corresponds to the knowledge that re-
sistance does not alter patients’ inhalation volume, which is
restricted by the lung volume.
Inhalation work is defined by equation [6] and corre-
sponds to the area under the curve of the lungpower versus
time curve.(19) Therefore, we see the highest performance
with the patients who have the highest lung capacity in
terms of power and volume, that is, the patients with asthma
in the study by Malmberg et al. and study by Jõgi et al. The
lower the resistance the higher the peak inhalation flow, but
shorter the duration. As expected from the literature, the
inhalation work was found to be reasonably similar between
the inhalers despite their resistances.(28) It is likely that this
parameter is also affected by the provided patient instruc-
tions.
Kamin-Haidl inhalation criteria were met for 96% of EH-
combi, 93% of EH-mono, 90% of Diskus, and 85% of TH
users. In a study by Malmberg et al., approximately 14% of
TH users struggled in producing sufficient lungpower.
Persson et al. had earlier reported 67% TH users meeting
60 L/min with a device having resistance near the com-
mercial products.(25) Unexpectedly, meeting the required
acceleration was most challenging for Diskus users in our
study. According to literature,(6) it should be the opposite for
lower resistance devices. There was no substantial differ-
ence between the devices in meeting the volume after the
peak criteria.
Results of our study show no compromise in lungpower
generation nor airflow acceleration for the highest resistance
device EH-mono or medium resistance Diskus having a
threshold of 30 L/min. Similar to Kamin-Haidl criteria, a
combination of inspiratory effort, acceleration, and inhala-
tion volume was proposed also by Azouz and Chrystyn.(29)
In literature, a higher inhaler device resistance is con-
sidered to improve lung deposition.(7,18) The considered
benefits include reduction of particle speed and thus reduced
oropharyngeal deposition, enabling higher lung deposi-
tion.(7,18) In addition, de Köning suggested that a higher
resistance device uses a smaller fraction (10% vs. 30%) of
the lung volume, achieving sufficient acceleration for drug
aerosolization. Therefore, excess lung volume provides ex-
tended inhalation duration that enables better fine drug
particle transport into the targeted lung regions.(7) Accord-
ing to a study in literature, a great majority of healthy vol-
unteers (82%) have found resistances of 0.021–0.047 OkPa
min/L acceptable range.(28)
Clark et al. discussed in favor of using inspiratory pres-
sure instead of inspiratory flow rate, which they state being
misleading in inhaler selection.(30) By nature, when the re-
sistance increases, PIF decreases and pressure drop in-
creases according to equation [1]. This effect is shown in the
study by Azouz et al. and Clark et al.(27,30) We believe that
the physical process of patient inspiratory muscle effort is
described by lungpower and therefore remains constant for a
specific patient regardless of inhaler resistance. Peak lung-
power means shown in Figure 1B are fairly similar re-
gardless of the device as expected if it describes the patient
capability. Achieved pressure drops, however, show marked
differences between the devices in Table 6. This is high-
lighted by the lack of overlap of CIs between the means of
peak pressure drops.
This can be illustrated further by comparison at, for ex-
ample, constant 10 kPa peak pressure drop, which is some-
times considered close to top range of human performance.
Achieving 10 kPa peak pressure drop for high resistance
EH-mono requires just 11.98 W, for medium to high resis-
tance EH-combi it requires 14.64 W, and for medium re-
sistance TH and Diskus 16.42 W and 19.52 W, respectively.
These calculation results suggest that generating the same
peak pressure drops for different inhaler devices would not
represent equal inspiratory effort and would therefore de-
scribe different patient populations when applied to different
inhalers.
Our results, illustrated in Table 7, indicate that at 60 and
90 L/min, the applied lungpower would differ drastically.
The fixed values of 30, 60, and 90 L/min airflows for in vitro
studies are therefore comparable only for devices of similar
resistances. We believe that the most adequate method for
in vitro flow rate investigations is to identify 10th, mean,
and 90th patient percentile flow rates (or PIFs or lung-
powers) for each device and patient group separately.
Malmberg and Jõgi have done so in their studies, which
were based on European Union’s (EU’s) Orally inhaled
products’ guideline.(21,22) Concerning the product perfor-
mance at different air flow percentiles, these studies re-
ported similar fine particle airflow dependency performance
and delivered dose performance for the EH-combi and TH
or Diskus within 10th to 90th percentile airflows.(21,22)
In real life, patient lungpower measurement could be
performed using device recording PIF or peak pressure drop,
acceleration, and volume after the peak, such as a tailored
spirometer. With known resistance, PIF or pressure drop can
be converted to lungpower using equation [3]. We believe
this data set provides valuable inhalation characterization
data and is a helpful tool for understanding the lungpower
concept, and peak lungpower distribution in intended patient
groups. It also explores the usefulness of Kamin-Haidl in-
halation criteria for assessing successful inhalation by pa-
tients.
Conclusions
It has occasionally been questioned whether higher re-
sistance inhaler devices would be more difficult to use for
the patient. In this study, the patients performed well in
lungpower generation, airflow acceleration, and inhalation
volume after the peak. These results indicate that inhaler
device resistance within the typical range of DPI resistances
(in this study 0.027–0.044 OkPa min/L) does not limit the
use of DPIs among typical patients with asthma or COPD.
Based on inhalation performance of the patients in our
data set, we consider Kamin-Haidl criteria incorporated with
peak lungpower as a potential option for investigating pa-
tient performance and confirming the suitable inhaler type
for the patient. Peak lungpower is a patient-specific char-
acteristic subject to the patients’ use of their inspiratory
muscles. Resistance is a device-specific fixed parameter, and
the generated flow rate or pressure drop is an interplay of
both inspiratory muscle use and resistance, as per equation
[1]. This inspiratory effort is previously reported,(25) neither
to correlate strongly with the clinical condition nor to the
peak expiratory flow, but rather the muscular strength of
the patient. Further studies with harmonized inhalation
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instructions are required to show whether lungpower would
be independent of the used inhaler. Reportedly, even severe
asthmatics can produce almost normal inhalations through
all tested devices.(25)
The use of Kamin-Haidl criteria could be further helped
by developing suitable analytical hand tools for clinicians
that provide lungpower outcome directly as a measurable.
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Evaluation of in vitro and in vivo flow rate dependency of
budesonide/formoterol Easyhaler. J Aerosol Med Pulm
Drug Deliv. 2014;27:329–340.
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